Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

（a joint stock company established in the People's Republic of China with limited liability）

（Stock Code：00719）

UNAUDITED FIRST QUARTER RESULTS OF 2021

（for the period commencing from 1 January 2021 to 31 March 2021）

This announcement is made pursuant to rules 13.09 and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the ''Listing Rules'') and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the "Board") of Shandong Xinhua Pharmaceutical Company Limited (the "Company") hereby announces the unaudited consolidated results of the Company and its subsidiaries (the "Group") for the 3 months ended 31 March 2021. The financial information set out in this announcement has been prepared in accordance with the CASBE (as defined under the Listing Rules) and has been reviewed and approved by the Audit Committee of the Board.

This announcement was prepared in both Chinese and English. In the event of any inconsistencies between the two versions, the Chinese version shall prevail.

I. KEY ACCOUNTING AND FINANCIAL DATA

Item

Operating income

Net profit attributable to shareholders of listed company

Net profit attributable to shareholders of listed company after deduction of non-recurring profit and loss

Net cash flow from operating activities

Basic earnings per share (RMB Yuan / Share)

Diluted earnings per share (RMB Yuan / Share)

Ratio of weighted average return on net assets (%)

Jan - Mar 2021

Jan - Mar 2020

Change as

(Unaudited)

(Unaudited)

compared to the

RMB Yuan

RMB Yuan

same period last

year

1,768,119,883.04

1,705,982,914.01

3.64%

100,276,326.14

86,286,544.27

16.21%

96,454,109.91

78,547,417.73

22.80%

89,368,875.29

104,929,221.85

(14.83%)

0.16

0.14

14.29%

0.16

0.14

14.29%

3.04%

2.88%

Increased by 0.16

percentage points

As at 31 Mar 2021

As at 31 Dec 2020

Change as

Item

(Unaudited)

(Audited)

compared to the

RMB Yuan

RMB Yuan

end of last year

Total assets

7,279,400,356.04

7,092,952,190.04

2.63%

Net assets attributable to the shareholders of listed company

3,359,487,089.39

3,223,793,819.25

4.21%

II. PROFIT AND LOSS ACCOUNT

Item

Jan - Mar 2021

Jan - Mar 2020

Consolidated

Parent company

Consolidated

Parent company

(Unaudited)

(Unaudited)

(Unaudited)

(Unaudited)

RMB Yuan

RMB Yuan

RMB Yuan

RMB Yuan

I. Gross revenue

1,768,119,883.04

949,499,126.18

1,705,982,914.01

989,274,388.58

Including: Operating revenue

1,768,119,883.04

949,499,126.18

1,705,982,914.01

989,274,388.58

II. Total operating costs

1,645,192,254.65

860,896,884.76

1,598,810,056.97

900,075,107.87

Including: Operating costs

1,254,025,842.08

724,312,604.93

1,222,472,164.24

748,283,913.04

Taxes and surcharges

12,969,521.98

5,828,517.57

14,141,461.75

6,573,733.35

Selling expenses

210,477,024.22

4,723,938.33

204,532,963.31

29,861,348.83

Administration expenses

79,177,668.02

58,216,330.02

72,321,500.54

46,651,160.65

R&D costs

77,494,772.47

56,252,178.12

74,898,770.72

57,820,767.20

Financial expenses

11,047,425.88

11,563,315.79

10,443,196.41

10,884,184.80

Including: Interest expense

13,897,685.02

13,839,939.09

14,527,145.14

14,508,758.91

Interest income

1,712,754.65

1,139,451.85

773,565.60

518,505.81

Add: Other income

5,812,444.68

5,390,736.31

10,545,393.22

10,212,266.72

Investment income (losses to

be listed with brackets)

1,699,415.30

1,699,415.30

(1,665,484.39)

(1,665,484.39)

Including: Return on investment on

joint ventures and joint ventures (losses

to be listed with brackets）

1,699,415.30

1,699,415.30

(1,665,484.39)

(1,665,484.39)

Credit impairment loss (losses to be

listed with brackets)

-

-

-

-

Assets impairment loss (losses to be

listed with brackets)

-

-

-

-

Gains from asset disposal (losses to be

listed with brackets)

20,665.92

-

70,471.19

69,609.70

III. Operating profits (losses to be

listed with brackets)

130,460,154.29

95,692,393.03

116,123,237.06

97,815,672.74

Add: non-operating income

36,502.45

6,300.00

18,102.60

6,703.63

Less: non-operating

expenditure

1,308,731.31

1,304,912.85

1,493,839.64

661,676.22

IV. Total profits (total loss to be listed

with brackets)

129,187,925.43

94,393,780.18

114,647,500.02

97,160,700.15

Less: income tax expense

23,512,136.43

13,904,154.73

21,164,263.83

14,823,927.68

V. Net profits (net loss to be listed with

brackets)

105,675,789.00

80,489,625.45

93,483,236.19

82,336,772.47

（ I ） According

to operation

continuity

1. Net profit from continued operations (net losses to be listed in

brackets)

105,675,789.00

80,489,625.45

93,483,236.19

82,336,772.47

2. Net profit from discontinued operations (net losses to be listed in brackets)

（II） According to ownership

1.

Net profit attributable

to

shareholders of parent company

100,276,326.14

-

86,286,544.27

-

2.

Minority interest income or loss

5,399,462.86

-

7,196,691.92

-

VI.

Net amount of other

comprehensive income after tax

790,288.84

903,570.40

(43,485,988.58)

(44,168,570.40)

Net amount of other comprehensive

income after tax attributable to the

shareholders of parent company

874,501.80

-

(43,630,963.67 )

-

  • I ） Other comprehensive income not subject to reclassification to profit or

loss

903,570.40

903,570.40

(44,168,570.40)

(44,168,570.40)

Changes in fair value of other

equity instruments investment

903,570.40

903,570.40

(44,168,570.40)

(44,168,570.40)

（II） Other comprehensive income

to be reclassified to profit or loss

(29,068.60)

-

537,606.73

-

Conversion difference of foreign

currency statement

(29,068.60)

-

537,606.73

-

Net amount of other comprehensive

income after tax attributable to the

minority shareholders

(84,212.96)

-

144,975.09

-

VII. Total comprehensive income

106,466,077.84

81,393,195.85

49,997,247.61

38,168,202.07

Total comprehensive income

attributable to the shareholders of parent

company

101,150,827.94

-

42,655,580.60

-

Total comprehensive income

attributable to the minority shareholders

5,315,249.90

-

7,341,667.01

-

VIII. Earnings per share:

(I) Basic earnings per share

0.16

-

0.14

-

(II) Diluted earnings per share

0.16

-

0.14

-

By Order of the Board

Shandong Xinhua Pharmaceutical Company Limited

Zhang Daiming

Chairman

9 April 2021, Zibo, PRC

As at the date of this announcement, the Board comprises:

Executive Directors:

Independent Non-executive Directors:

Mr. Zhang Daiming (Chairman)

Mr. Pan Guangcheng

Mr. Du Deping

Mr. Zhu Jianwei

Mr. He Tongqing

Mr. Lo Wah Wai

Non-executive Directors:

Mr. Xu Lie

Mr. Cong Kechun

Attachments

  • Original document
  • Permalink

Disclaimer

Shandong Xinhua Pharmaceutical Company Ltd. published this content on 09 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 April 2021 08:37:08 UTC.